Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Praram 9 Hospital PCLBKK:PR9 -0.56%88 EV-to-EBITDA is 8.58 as of Aug. 16, 2026, which is 35% below its 10-year median of 13.13. GuruFocus rates BKK:PR9 with a GF Score™ of 88/100 and a GF Value™ of ฿23.71 (Modestly Undervalued). Among 511 Healthcare Providers & Services companies, Praram 9 Hospital PCL ranks better than 62.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Praram 9 Hospital PCL's enterprise value is ฿11,283 Mil.
Praram 9 Hospital PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ฿1,314 Mil. Therefore, Praram 9 Hospital PCL's EV-to-EBITDA for today is 8.58.
The historical rank and industry rank for Praram 9 Hospital PCL's EV-to-EBITDA or its related term are showing as below:
BKK:PR9'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.74 Med: 13.13 Max: 21.2
Current: 8.58
During the past 12 years, the highest EV-to-EBITDA of Praram 9 Hospital PCL was 21.20. The lowest was 6.74. And the median was 13.13.
BKK:PR9's EV-to-EBITDA is ranked better than 62.43% of 511
companies
in the Healthcare Providers & Services industry
Industry Median: 10.69
vs BKK:PR9: 8.58
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Praram 9 Hospital PCL's PE Ratio (TTM) for today is calculated as:
Praram 9 Hospital PCL's share price for today is ฿17.90.
Praram 9 Hospital PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿1.016.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Praram 9 Hospital PCL EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Praram 9 Hospital PCL's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Praram 9 Hospital PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Praram 9 Hospital PCL EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Praram 9 Hospital PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Praram 9 Hospital PCL's EV-to-EBITDA falls into.
Praram 9 Hospital PCL's current Enterprise Value is ฿11,283 Mil.
Praram 9 Hospital PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿1,314 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Praram 9 Hospital PCL (BKK:PR9) has a EV-to-EBITDA of 8.58 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Praram 9 Hospital PCL. This is 35% below median its historical median of 13.13. Over the past decade, Praram 9 Hospital PCL's EV-to-EBITDA has ranged from 6.74 to 21.20. According to the industry distribution chart, Praram 9 Hospital PCL ranks #192 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 37.6%.
Is Praram 9 Hospital PCL's EV-to-EBITDA too high?
Praram 9 Hospital PCL's current EV-to-EBITDA of 8.58 is 35% below median its 10-year median of 13.13. Over the past 10 years, this metric has ranged from a low of 6.74 to a high of 21.20. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.69. Praram 9 Hospital PCL's value of 8.58 is 19.7% below this industry median. Based on the distribution chart, Praram 9 Hospital PCL ranks #192 out of 511 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Praram 9 Hospital PCL has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Praram 9 Hospital PCL's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Praram 9 Hospital PCL ranks #192 out of 511 companies for EV-to-EBITDA. This puts Praram 9 Hospital PCL in the upper half of its industry. The industry median EV-to-EBITDA is 10.69. Praram 9 Hospital PCL's value of 8.58 is 19.7% below this benchmark. Historically, Praram 9 Hospital PCL's own EV-to-EBITDA has ranged from 6.74 to 21.20 over the past decade. While the company's 10-year median is 13.13 vs. the industry median of 10.69, Praram 9 Hospital PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.69, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Praram 9 Hospital PCL's current EV-to-EBITDA of 8.58 is 19.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Praram 9 Hospital PCL. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Praram 9 Hospital PCL's current EV-to-EBITDA is 8.58, which is 35% below median its own 10-year median of 13.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praram 9 Hospital PCL stock overvalued right now?
Based on GuruFocus' analysis, Praram 9 Hospital PCL (BKK:PR9) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿23.71, compared to a current price of ฿17.90 — trading 24.5% below its estimated fair value. The current EV-to-EBITDA is 8.58, which is 35% below median its 10-year median of 13.13 and 19.7% below the Healthcare Providers & Services industry median of 10.69. Praram 9 Hospital PCL's overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Praram 9 Hospital PCL (BKK:PR9), the current EV-to-EBITDA is 8.58 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Praram 9 Hospital PCL (BKK:PR9) Overvalued in 2026?
Based on GuruFocus' analysis, Praram 9 Hospital PCL stock appears to be undervalued.
The current stock price of ฿17.90 is trading 24.5% below its estimated GF Value™ of ฿23.71.
GuruFocus considers Praram 9 Hospital PCL to be Modestly Undervalued.
Key valuation signals for BKK:PR9:
EV-to-EBITDA: 8.58 (35% below median its 10-year median of 13.13)
GF Value™: ฿23.71 vs. price of ฿17.90 (24.5% below fair value)
Industry Position: 19.7% below the Healthcare Providers & Services median (#192 of 511)
No single metric tells the full story. See the BKK:PR9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Praram 9 Hospital PCL is engaged in hospital operations in Bangkok. The company operates an overnight general hospital under the name of Praram 9 Hospital. The revenue derived from hospital operations mainly consists of medical fees, hospital room sales, and medicine sales. Geographically, the company operates only in Thailand.
88GF Score
Get the complete analysis for BKK:PR9
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:PR9 has been successfully added to your 
